The Scottish Medicines Consortium has issued its monthly advice on new medicines.
Sitagliptin (Januvia®) has been accepted for restricted use in patients with type 2 diabetes. It is recommended that this agent is used in patients where diet and exercise combined with metformin does not provide adequate glycaemic control and sulphonylureas are contraindicated or not tolerated. They should be considered an alternative to glitazones.
Escitalopram (Cipralex®) has been rejected for the treatment of obsessive compulsive disorder. The economic data submitted was not sufficiently robust to gain acceptance.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected medicines should be avoided.
|« HDL and LDL both predict CV risk||Early intervention prevents recurrent stroke »|